Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
J. Le Lorier, G. Gregoire, A. Benhaddad, J. Lapierre, F. Derderian.
Discrepancies between meta-analyses and subsequent large randomized, controlled trials.
N Engl J Med, 337 (1997), pp. 536-542
[3.]
M.R. Tramer, D.J.M. Reynolds, R.A. Moore, H.J. McQuay.
Impact of covert duplicate publication on meta-analysis: a case study.
Bmj, 315 (1977), pp. 635-640
[4.]
L. Speroff, R.H. Glass, N.G. Kase.
Oral contraception.
Clinical Gynecologic endocrinology and infertility, 6.a ed, pp. 867-945
[5.]
H. Jick, L.E. Derby, M.W. Myers, C. Vasilakis, K.M. Newton.
Risk of hospital admission for idiopathic venous tromboembolism among users of postmenopausal oestrogens.
Lancet, 348 (1996), pp. 981-983
[6.]
E. Daly, M.P. Vessey, M.M. Hawkins, J.L. Carson, P. Gough, S. Marsh.
Risk of venous thromboembolism in users of hormone replacement therapy.
Lancet, 348 (1996), pp. 977-980
[7.]
G. Lowe.
Effects of estrogen on thromboembolism.
HRT and thromboembolism. Round Table Series 50. Royal Society of Medicine, pp. 3-16
[8.]
S. Pérez Guttham, L.A. García Rodríguez, J. Castellsague, A. Duque.
Hormone replacement therapy and risk of venous thromboembolism: population based caso-control study.
Bmj, 314 (1997), pp. 796-800
[9.]
D. Grady, S.B. Hulley, C. Furberg.
Venous thromboembolic events associated with hormone replacement therapic.
Jama, 278 (1997), pp. 477-483
[10.]
M. Falkeborn, I. Persson, A. Terent, H.O. Adami, H. Litheel, R. Bergström.
Hormone replacement therapy and the risk of stoke. Follow-up of a population-based cohort in Sweden.
Arch Intern Med, 153 (1993), pp. 1201-1209
[11.]
F.F. Finucane, J.H. Madans, T.L. Bush, P.H. Wolf, J.C. Kleinman.
Decreased risk of stroke among postmenopausal hormone users. Results from a National Cohort.
Arch Intern Med, 153 (1993), pp. 73-79
[12.]
D. Grady, S.M. Rubin, D.B. Petitti, et al.
Hormone therapy to prevent disease and prolong life in postmenopausal women.
Ann Intern Med, 117 (1992), pp. 1016-1037
[13.]
A.T. Pedersen, O. Lidegaard, S. Kreiner, B. Ottesen.
Hormone replacement therapy and risk of non fatal stroke.
Lancet, 350 (1997), pp. 1277-1283
[14.]
Writting Group for the PEPI Trial.
Effects of estrogen or estrogen/ progestin regimens on heart disease risk factors in postmenopausal women.
Jama, 273 (1995), pp. 199-208
[15.]
D.C. Smith, R. Prentice, D.J. Thompson, W.L. Herrmman.
Association of exogenous estrogen and endometrial carcinoma.
N Engl J Med, 293 (1975), pp. 1164-1167
[16.]
Conferencia de Consenso.
Criterios de administración de la THS, Sociedad Española para el Estudio de la Menopausia (AEEM), (1994),
[17.]
D. Grady, T. Gebretsadik, K. Kerlikowske, V. Ernster, D. Petitti.
Hormone Replacement Therapy and Endometrial Cancer Risk: a meta-analysis.
Obstet Gynecol, 85 (1995), pp. 304-313
[18.]
R.D. Jr. Gambrell.
The prevention of endometrial cancer in postmenopausal women with progestagens.
Maturitas, 1 (1978), pp. 107-112
[19.]
D. Archer, J. Pickar, F. Bottiglioni.
Bleeding patterns in postmenopausal women taking continous combined or sequential regimens of conjugated estrogens with medroxiprogesterone acetate.
Obstet Gynecol, 83 (1994), pp. 686-692
[20.]
S.A. Beresford, N.S. Weiss, L.F. Voigt, B. McKnight.
Risk of endometrial cancer in relation to use of estrogen combined with cyclic progestagen therapy in postmenopausal women.
Lancet, 349 (1997), pp. 458-461
[21.]
E. Barret-Connor, D. Grady.
Hormone replacement therapy, heart disease and other considerations.
Ann Rev Public Health, 19 (1998), pp. 55-72
[22.]
W.T. Creasman, D. Henderson, W. Hinshaw, D.L. Clarke-pearson.
Estrogen replacement therapy in the patient treated for endometrial cancer.
Obstet Gynecol, 67 (1986), pp. 326-330
[23.]
R.B. Lee, T.W. Burke, R.C. Park.
Estrogen replacement therapy following treatment for stage I endometrial carcinoma.
Gynecol Oncol, 36 (1990), pp. 189-191
[24.]
J.A. Chapman, P. Di Saia, K. Osann, P.D. Roth, D.L. Gillote, M.L. Berman.
Estrogen replacement in surgical stage I and II endometrial cancer survivors.
Am J Obstet Gynecol, 175 (1996), pp. 1195-1200
[25.]
V. Mahavni, R.E. Buller.
Estrogen replacement therapy in endometrial and breast cancer survivors.
Clin Obstet Gynecol, 42 (1999), pp. 863-875
[26.]
American College of Obstetricians and Gynecologist ACOG.
Educational Bulletin 247.
Hormone therapy, (mayo de 1998),
[27.]
Physicians' Desk Reference.
Medical Economics Company Inc, (1999),
[28.]
J. Balasch, J. González-Merlo.
Gestágenos, terapéutica hormonal sustitutiva y cáncer de mama.
Prog Obstet Ginecol, 37 (1994), pp. 595-599
[29.]
R. Comino, J.J. Fernández, D. Lubian.
Tratamiento hormonal sustitutivo y cáncer de mama.
Prog Ostet Gynecol, 40 (1997), pp. 303-330
[30.]
B. Armstrons.
Oestrogen therapy after the menopause, boon or bone?.
Med J Aust, 148 (1998), pp. 213-214
[31.]
W.D. Dupont, D.L. Page.
Menopausal estrogen replacement therapy and breast cancer.
Arch Intern Med, 151 (1991), pp. 67-72
[32.]
K.K. Steinberg, S.B. Thacker, S.J. Smith, D.F. Stroup, M.M. Zack, D. Flanders, et al.
A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer.
Jama, 265 (1991), pp. 1985-1990
[33.]
D. Grady, S.M. Rubin, D.B. Petiti, et al.
Hormone therapy to prevent disease and prolong life in postmenopausal women.
Am Intern Med, 117 (1992), pp. 1016-1037
[34.]
M. Sillero-Arenas, M. Delgado, R. Rodríguez, A. Bueno, R. Gálvez.
Menopausal hormone replacement therapy and breast cancer: a metaanalysis.
Obstet Gynecol, 79 (1992), pp. 286-294
[35.]
G.A. Colditz, K.M. Egan, M.J. Stamfer.
Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies.
Am J Obstet Gynecol, 168 (1993), pp. 1473-1480
[36.]
M. Delgado, M. Sillero-Arenas, R. Sánchez.
Terapia hormonal sustitutiva en la menopausia y riesgo de cáncer de mama. Un metaanálisis.
Prog Obstet Gynecol, 37 (1994), pp. 601-614
[37.]
G.A. Colditz, S.E. Hankinson, D.J. Hunter, W.C. Willet, J.E. Manson, M.J. Stampfer, et al.
The use of estrogen and progestins and the risk of breast cancer in postmenopausal women.
N Engl J Med, 332 (1995), pp. 1589-1593
[38.]
J.L. Stanford, N.S. Weiss, L.F. Voigt, J.R. Daling, L.A. Habel, M.A. Rossing.
Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women.
Jama, 274 (1996), pp. 137-142
[39.]
Cancer Collaborative Group on Hormonal Factor in Breast.
Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer.
Lancet, 350 (1997), pp. 1047-1059
[40.]
G.A. Colditz, B. Rosmer.
For de Nurses' Health Study Research Group. Use of estrogen plus progestin is associated with greater increase in breast cancer risk than estrogen alone.
Am J Epidemiol, 147 (1998), pp. 645
[41.]
I. Persson, E. Weiderpass, L. Bergkvist, et al.
Risk's of breast and endometrial cancer after estrogen and progestin replacement.
Cancer Causes Control, 10 (1999), pp. 253-260
[42.]
C. Schairer, J. Lubin, S. Sturgeon, et al.
Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk.
Jama, 283 (2000), pp. 485-491
[43.]
R.K. Ross, A. Paganini-Hill, P.C. Wan, et al.
Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin.
J Natl Cancer Inst, 92 (2000), pp. 328-332
[45.]
M.B. Laya, E.B. Larson, S.H. Taplin, E. White.
Effect of estrogen replacement therapy on the specifity and sensibility of screening mammography.
J Nat Cancer Inst, 88 (1996), pp. 43-49
[46.]
E. Moreno, F. Escudero, J.L. Dueñas.
Modificaciones de los patrones radiológicos mamarios en usuarias de THS a largo plazo.
Prog Obstet Ginecol, 42 (1999), pp. 113-119
[47.]
N.F. Boyd, J.W. Byng, R.A. Jong, E.K. Fishell, L.E. Little, A.B. Miller, et al.
Quantitative classification of mammographic densities and breast cancer risk: results from Canadian National Breast Cancer Screening Study.
J Nat Cancer Inst, 87 (1995), pp. 670-675
[48.]
L.J. Solin, K. Fox, D. August, et al.
Breast cancer.
Principles and practice of gynecologic oncology. Filadelfia, pp. 1079-1142
[49.]
B.A. Stoll, S. Parbhoo.
Treatment of menopausal symtoms in breast cancer patients.
Lancet, 1 (1988), pp. 1278-1279
[50.]
T.J. Powles, T. Hicksh, O. Casey, M. O'Brien.
Hormone replacement after breast cancer.
Lancet, 342 (1993), pp. 60-61
[51.]
A.G. Wile, R.W. Opfell, D.A. Margileth.
Hormone replacement therapy in previously treated breast patients.
Am J Surg, 165 (1993), pp. 372-375
[52.]
J.A. Eden, T. Bush, S. Nand, B.G. Wren.
A case-control study of combined continous estrogen progestin replacement therapy among women with a personal history of breast cancer.
Menopause, 2 (1995), pp. 67-72
[53.]
P.I. Di Saia, E.A. Grosen, T. Kurosaki, M. Gildea, B. Cowan, H. Anton- Cuiver.
Hormone replacement therapy in breast cancer survivors: a cohort study.
Am J Obstet Gynecol, 174 (1996), pp. 1494-1498
[54.]
R. Vassilopoulou-Sellin, R. Theriaault.
Randomized prospective trial of estrogen replacement therapy in women with history of breast cancer.
Monogr Nat Cancer Inst, 16 (1994), pp. 153-159
[55.]
R. Santen, K. Pritchard, H. Burger.
The consensus conference on treatment of estrogen deficiency symptoms in women surviving breast cancer.
Obstet Gynecol Surv, 53 (1998), pp. 1-83
[56.]
P.P. Garg, K. Kerlikowske, L. Subak, D. Grady.
Hormone replacement therapy and the risk of epithelial ovarian cacinoma: a meta-analysis.
Obstet Gynecol, 22 (1998), pp. 472-479
[57.]
C. Rodríguez, A.V. Patel, E.E. Calle, E.J. Jacob, M.J. Thun.
Estrogen replacement therapy and ovarian cancer mortality in large prospective study of US women.
Jama, 285 (2001), pp. 1460-1465
[58.]
D.B. Petitti, S.P. Sidney, J.A. Perlman.
Increased risk of cholocystectomy in users supplemental estrogen.
Gastroenterol, 94 (1988), pp. 91-95
[59.]
R.A. Lobo.
Treatment of the postmenopausal woman. Nueva York Raven Press, (1994),
[60.]
J. Coope, J.M. Thompson, L. Oller.
Effects of “natural oestrogen” replacement therapy on menopausal sympoms and blood clotting.
Bmj, 4 (1975), pp. 139-143
[61.]
G.A. Gleendale, B.A. Rebousin, P. Hogan, V.M. Barnebei, S. Shumaker, et al.
Symptom relief and side effects of postmenopausal hormones: results from the postmenopausal estrogen/ progestin interventions trial.
Obstet Gynecol, 92 (1998), pp. 982-988
[62.]
L. Cardozo, G. Bachmann, D. MacClish, D. Fonda, L. Birgerson.
Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the hormones and urogenital therapy commitee.
Obstet Gynecol, 92 (1998), pp. 722-727
[63.]
R. Raz, W.E. Stamm.
A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections.
N Engl J Med, 329 (1993), pp. 753-756
[64.]
Writing Group the PEPI Trial.
Effects of hormone therapy on bone mineral density.
Jama, 276 (1996), pp. 1389-1396
[65.]
L. Speroff, J. Rowan, J. Symons, H. Genant, W. Wilborn.
The comparative effect on bone density, endometrium, and lipids of continous hormones as replacement therapy (CHART study). A randomized controlled trial.
Jama, 276 (1996), pp. 1397-1403
[66.]
P.J. Meunier.
Medicina basada en la evidencia y osteoporosis: comparación de los datos sobre reducción del riesgo de fractura procedentes de estudios clínicos aleatorios en osteoporosis.
Int J Clin Pract, 53 (1999), pp. 122-129
[67.]
J.L. Dueñas Díez, A. Albert Matea, M. La Calle Marcos.
Riesgos y beneficios de la terapia hormonal sustitutiva desde la perspectiva de la medicina basada en la evidencia.
Clin Invest Ginecol Obstet, 26 (1999), pp. 358-372
[68.]
E.G. Lufkin, H.W. Wahner, W.M. O'Fallon, S.F. Hodgson, M.A. Kotowicz, A.W. Lane, et al.
Treatment of postmenopausal osteoporosis with transdermal estrogen.
Ann Intern Med, 117 (1992), pp. 1-9
[69.]
S.R. Cummings, D.M. Black, S.M. Rubin.
Lifetime risks of hip. Colles or vertebral fracture and coronary heart disease among white postmenopausal women.
Arch Intern Med, 149 (1989), pp. 2445-2448
[70.]
L. Mosca, C.h.J.E. Manson, S.E. Sutherland, R.D. Langer, T. Manolio, E. Barret-Connor.
Cardiovascular disease in women. A statement for health care professionals from amearica heart association.
Circulation, 96 (1997), pp. 2468-2482
[71.]
H. Tunstall-pedoe.
Myth and paradox of coronary risk and the menopause.
Lancet, 351 (1998), pp. 1425-1427
[72.]
E. Barret-Connor.
Sex differences in coronary heart disease. Why are women so superior? The 1995 ancel keys lecture.
Circulation, 95 (1997), pp. 252-264
[73.]
J.B. McKinlay.
Some contributions from the social system to gender inequalites in heart disease.
J Health Soc Behav, 37 (1996), pp. 1-26
[74.]
R. Pascual, V. Gil, J. Marino.
Menopausia y riesgo cardiovascular. Alcance y limitaciones del tratamiento hormonal sustitutivo.
Clin Invest Arteriosclerosis, 10 (1998), pp. 247-257
[75.]
R.D. Gorsky, J.P. Koplan, H.B. Peterson, S.B. Tacker.
Relative risks and benefits of long-term estrogen replacement therapy: a decision analysis.
Obstet Gynecol, 82 (1994), pp. 161-166
[76.]
F. Grodstein, M.J. Stampfer, J.E. Manson, G.A. Colditz, W.C. Willet, B. Rosner, et al.
Postmenopausal estrogen and progestin use and the risk of cardiovascular disease.
N Engl J Med, 335 (1996), pp. 453-461
[77.]
E. Hemminki, K. MacPherson.
Impact of menopausal hormone therapy on cardiovascualr events and cancer: pooled data from clinical trials.
Bmj, 315 (1997), pp. 149-153
[78.]
S. Hulley, D. Grady, T. Bush, C. Furberg, D. Herrington, B. Riggs, et al.
Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.
Jama, 280 (1998), pp. 605-613
[79.]
D. Robinson, L. Friedman, R. Marcus, et al.
estrogen replacement therapy and memory in older women.
J Am Geriatr Soc, 42 (1994), pp. 219-222
[80.]
B.B. Sherwin.
Estrogen effects on cognition in menopausal women.
Neurology, 48 (1997), pp. 521-566
[81.]
E. Barret-Connor, D. Kritz-Silverstein.
Estrogen replacement therapy and cognitive function in older women.
Jama, 269 (1993), pp. 2637-2641
[82.]
K. Yaffe, G. Sawwaya, I. Lieberburg, D. Grady.
Estrogen therapy in postmenopausal women: effects on cognitive function and dementia.
Jama, 279 (1998), pp. 688-695
[83.]
J.E. Zweifel, W.H. O'Brien.
A meta-analysis of the effect of HRT upon depressed mood.
Psychoneuroendocrinology, 22 (1997), pp. 189-212
[84.]
E.C. Ditkoff, W.G. Crary, M. Cristo, R.A. Lobo.
Estrogen improves psichological functioning in asymptomatic postmenopausal women.
Obstet Gynaecol, 78 (1991), pp. 991-995
[85.]
N. Best, M. Rees, D. Barlow, et al.
Effect of estradiol implant on noradrenergic funtion and mood in menopausal patients.
Psychoneuroendocrinology, 17 (1992), pp. 87-93
[86.]
G. Gramegna, J.E. Blumel, S. Jara, I. Schiattino, F. Lolas.
Effects of estrogen supplementation on psychological variables in climateric women.
Rev Med Chil, 124 (1996), pp. 1240-1244
[87.]
B. Sherwin, B.E. Surany-Cadotte.
Up regulatory effect of estrogen on platelet 3H-imipramine binding sites in surgically menopaused women.
Biol Psych, 28 (1990), pp. 339-348
[88.]
E.L. Klaiber, D.M. Broverman, W. Vogel, et al.
Estrogen replacement therapy for severe persistent depression in women.
Arch Gen Psych, 36 (1979), pp. 550-554
[89.]
A. Paganini-Hill, V.W. Henderson.
Estrogen deficiency and risk of Alzheimer's disease in women.
Am J Epidemiol, 140 (1994), pp. 256-261
[90.]
D.E. Brenner, W.A. Kukull, A. Stergachis, et al.
Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease: A population-based case-control study.
Am J Epidemiol, 140 (1994), pp. 262-267
[91.]
S.J. Birge.
The role of estrogen in the treatment of Alzheimer's disease.
Neurology, 48 (1997), pp. 36-41
[92.]
V.W. Henderson, A. Paganini-Hill, C.K. Emanuel, et al.
Estrogen replacement therapy in older women. Comparison between Alzheimer's disease cases and nondemented control subject.
Arch Neurol, 51 (1994), pp. 896-900
[93.]
K.F. Mortel, J.S. Meyer.
Lack of postmenopausal estrogen replacement therapy and the risk of dementia. J Neuropsychiatry.
Clin Neurosci, 7 (1995), pp. 334-337
[94.]
A. Lerner, R. Cole, S. Debanne, et al.
Immunological and endocrine conditions in an Alzheimer's disease case-control study.
Neuroepidemiology, 14 (1995), pp. 307
[95.]
M. Baldereschi, A. Di Carlo, S. Maggi, et al.
Estrogen replacement therapy and the risk of dementia in the Italian Longitudinal Study on Aging.
Eur J Neurol, 3 (1996), pp. 85-86
[96.]
M.X. Tang, D. Jacobs, Stern, et al.
Effect of estrogen during menopause on risk and age at onset of Alzheimer's disease.
Lancet, 348 (1996), pp. 429-432
[97.]
S.C. Waring, W.A. Rocca, R.C. Petersen, E. Kokmen.
Postmenopausal estrogen replacement therapy and Alzheimer's disease: A population-based study in Rochester, Minnesota.
Neurology, 48 (1997), pp. 79
[98.]
C. Kawas, S. Resmick, A. Morrison, et al.
A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: The Baltimore Longitudinal Study of Aging.
Neurology, 48 (1997), pp. 1517-1521
[99.]
K. Yaffe, G. Sawwaya, I. Lieberburg, D. Grady.
Estrogen therapy in postmenopausal women: effects on cognitive function and dementia.
Jama, 279 (1998), pp. 688-695
[100.]
E.J. Jacobs, E. White, N.S. Weiss.
Exogenous hormones, reproductive history and colon cancer (Seattle, Washington, USA).
Cancer Causes and Control, 5 (1994), pp. 359-366
[101.]
E.E. Calle, L. Miracle-MacHill, M.J. Thun, C.W. Heath.
Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women.
J Natl Cancer Inst, 87 (1995), pp. 517-523
[102.]
B.A. Newcomb, B.E. Storer.
Postmenopausal hormone use and risk of large bowel cancer.
J Natl Cancer Inst, 87 (1995), pp. 1067-1071
[103.]
J.A. Cauley, D.G. Seeley, W.S. Browner, K. Ensind, L.H. Kuller, R.C. Lipschutz, et al.
Estrogen replacement therapy and mortality among older women.
Arch Intern Med, 157 (1997), pp. 2181-2187
[104.]
B.E. Henderson, A. Paganini-Hill, R.K. Ross.
Decreased mortality in users of estrogen replacement therapy.
Arch Intern Med, 151 (1991), pp. 75-78
[105.]
D. Grady, S. Rubin, D.B. Petitti, C.S. Fox, D. Black, B. Ettinger, et al.
Hormone therapy to prevent disease and prolong life in postmenopausal women.
Ann Intern Med, 117 (1992), pp. 1016-1037
[106.]
F. Grodstein, M.J. Stampfer, G.A. Colditz, W.C. Willet, J.E. Manson, et al.
Postmenopausal hormone therapy and mortality.
N Engl J Med, 336 (1997), pp. 1769-1775
Copyright © 2001. Sociedad Española de Ginecología y Obstetricia